Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 161

1.

Vaccination Guidelines for Patients With Immune-Mediated Disorders on Immunosuppressive Therapies.

Papp KA, Haraoui B, Kumar D, Marshall JK, Bissonnette R, Bitton A, Bressler B, Gooderham M, Ho V, Jamal S, Pope JE, Steinhart AH, Vinh DC, Wade J.

J Cutan Med Surg. 2018 Nov 21:1203475418811335. doi: 10.1177/1203475418811335. [Epub ahead of print]

PMID:
30463418
2.

Real-World Tocilizumab Use in Patients with Rheumatoid Arthritis in Canada: 12-Month Results From an Observational, Noninterventional Study.

Haraoui B, Jamal S, Ahluwalia V, Fung D, Manchanda T, Khraishi M.

Rheumatol Ther. 2018 Dec;5(2):551-565. doi: 10.1007/s40744-018-0130-6. Epub 2018 Oct 28.

3.

Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study.

Takeuchi T, Genovese MC, Haraoui B, Li Z, Xie L, Klar R, Pinto-Correia A, Otawa S, Lopez-Romero P, de la Torre I, Macias W, Rooney TP, Smolen JS.

Ann Rheum Dis. 2018 Sep 7. pii: annrheumdis-2018-213271. doi: 10.1136/annrheumdis-2018-213271. [Epub ahead of print]

4.

A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population.

Kivitz AJ, Cohen S, Keystone E, van Vollenhoven RF, Haraoui B, Kaine J, Fan H, Connell CA, Bananis E, Takiya L, Fleischmann R.

Semin Arthritis Rheum. 2018 Jul 19. pii: S0049-0172(17)30815-6. doi: 10.1016/j.semarthrit.2018.07.006. [Epub ahead of print]

5.

High Adherence to System-Level Performance Measures for Rheumatoid Arthritis in a National Early Arthritis Cohort Over Eight Years.

Barber CEH, Schieir O, Lacaille D, Marshall DA, Barnabe C, Hazlewood G, Thorne JC, Ahluwalia V, Bartlett SJ, Boire G, Haraoui B, Hitchon C, Keystone E, Tin D, Pope JE, Denning L, Bykerk VP; Canadian Early Arthritis Cohort Investigators.

Arthritis Care Res (Hoboken). 2018 Jun;70(6):842-850. doi: 10.1002/acr.23439. Epub 2018 Mar 25.

6.

Dose Escalation and Co-therapy Intensification Between Etanercept, Adalimumab, and Infliximab: The CADURA Study.

Thorne C, Boire G, Chow A, Garces K, Liu F, Poulin-Costello M, Walker V, Haraoui B.

Open Rheumatol J. 2017 Oct 24;11:123-135. doi: 10.2174/1874312901711010123. eCollection 2017.

7.

Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment.

Curtis JR, Winthrop K, O'Brien C, Ndlovu MN, de Longueville M, Haraoui B.

Arthritis Res Ther. 2017 Dec 15;19(1):276. doi: 10.1186/s13075-017-1466-y.

8.

Defining and characterizing sustained remission in patients with rheumatoid arthritis.

Curtis JR, Trivedi M, Haraoui B, Emery P, Park GS, Collier DH, Aras GA, Chung J.

Clin Rheumatol. 2018 Apr;37(4):885-893. doi: 10.1007/s10067-017-3923-z. Epub 2017 Dec 9.

9.

Overweight, Obesity, and the Likelihood of Achieving Sustained Remission in Early Rheumatoid Arthritis: Results From a Multicenter Prospective Cohort Study.

Schulman E, Bartlett SJ, Schieir O, Andersen KM, Boire G, Pope JE, Hitchon C, Jamal S, Thorne JC, Tin D, Keystone EC, Haraoui B, Goodman SM, Bykerk VP; CATCH Investigators.

Arthritis Care Res (Hoboken). 2018 Aug;70(8):1185-1191. doi: 10.1002/acr.23457. Epub 2018 Jul 13.

PMID:
29193840
10.

Early Rheumatoid Arthritis Presentation, Treatment, and Outcomes in Aboriginal Patients in Canada: A Canadian Early Arthritis Cohort Study Analysis.

Nagaraj S, Barnabe C, Schieir O, Pope J, Bartlett SJ, Boire G, Keystone E, Tin D, Haraoui B, Thorne JC, Bykerk VP, Hitchon C; Canadian Early Arthritis Cohort Study Investigators.

Arthritis Care Res (Hoboken). 2018 Aug;70(8):1245-1250. doi: 10.1002/acr.23470.

PMID:
29125904
11.

Real-world validation of the minimal disease activity index in psoriatic arthritis: an analysis from a prospective, observational, biological treatment registry.

Rahman P, Zummer M, Bessette L, Baer P, Haraoui B, Chow A, Kelsall J, Kapur S, Rampakakis E, Psaradellis E, Lehman AJ, Nantel F, Osborne B, Tkaczyk C.

BMJ Open. 2017 Aug 30;7(8):e016619. doi: 10.1136/bmjopen-2017-016619.

12.

Patterns of tocilizumab use, effectiveness and safety in patients with rheumatoid arthritis: core data results from a set of multinational observational studies.

Haraoui B, Casado G, Czirják L, Taylor A, Bernasconi C, Reiss W, Caporali R.

Clin Exp Rheumatol. 2017 Nov-Dec;35(6):899-906. Epub 2017 Apr 28.

PMID:
28516886
13.

Thresholds for the 28-joint disease activity score (DAS28) using C-reactive protein are lower compared to DAS28 using erythrocyte sedimentation rate in early rheumatoid arthritis.

Kuriya B, Schieir O, Lin D, Xiong J, Pope J, Boire G, Haraoui B, Thorne JC, Tin D, Hitchon C, Jamal S, Keystone E, Bykerk VP; CATCH Investigators.

Clin Exp Rheumatol. 2017 Sep-Oct;35(5):799-803. Epub 2017 Mar 23.

PMID:
28339365
14.

The effect of rheumatoid arthritis-associated autoantibodies on the incidence of cardiovascular events in a large inception cohort of early inflammatory arthritis.

Barra LJ, Pope JE, Hitchon C, Boire G, Schieir O, Lin D, Thorne CJ, Tin D, Keystone EC, Haraoui B, Jamal S, Bykerk VP; CATCH group.

Rheumatology (Oxford). 2017 May 1;56(5):768-776. doi: 10.1093/rheumatology/kew474.

PMID:
28073956
15.

Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.

Smolen JS, Burmester GR, Combe B, Curtis JR, Hall S, Haraoui B, van Vollenhoven R, Cioffi C, Ecoffet C, Gervitz L, Ionescu L, Peterson L, Fleischmann R.

Lancet. 2016 Dec 3;388(10061):2763-2774. doi: 10.1016/S0140-6736(16)31651-8. Epub 2016 Nov 15. Erratum in: Lancet. 2017 Feb 4;389(10068):e2.

PMID:
27863807
16.

Predicting Low Disease State and Remission in Early Rheumatoid Arthritis in the First Six Months, Comparing the Simplified Disease Activity Index and European League Against Rheumatism Response Measures: Results From an Early Arthritis Cohort.

Omair MA, Keystone E, Bykerk V, Lin D, Xiong J, Sun Y, Boire G, Thorne JC, Tin D, Pope J, Hitchon C, Haraoui B, Akhavan PS; Canadian Early Arthritis Cohort Investigators.

Arthritis Care Res (Hoboken). 2017 May;69(5):737-741. doi: 10.1002/acr.22983. Epub 2017 Apr 7.

17.

Self-reported comorbidity is common in early inflammatory arthritis and associated with poorer function and worse arthritis disease outcomes: results from the Canadian Early Arthritis Cohort.

Hitchon CA, Boire G, Haraoui B, Keystone E, Pope J, Jamal S, Tin D, Thorne C, Bykerk VP; CATCH investigators.

Rheumatology (Oxford). 2016 Oct;55(10):1751-62. doi: 10.1093/rheumatology/kew061. Epub 2016 Jun 21.

PMID:
27330161
18.

Identifying flares in rheumatoid arthritis: reliability and construct validation of the OMERACT RA Flare Core Domain Set.

Bykerk VP, Bingham CO, Choy EH, Lin D, Alten R, Christensen R, Furst DE, Hewlett S, Leong A, March L, Woodworth T, Boire G, Haraoui B, Hitchon C, Jamal S, Keystone EC, Pope J, Tin D, Thorne JC, Bartlett SJ.

RMD Open. 2016 May 26;2(1):e000225. doi: 10.1136/rmdopen-2015-000225. eCollection 2016.

19.

Limitations in the Full Reporting of Systematic Literature Review.

Haraoui B.

J Rheumatol. 2016 May;43(5):994. doi: 10.3899/jrheum.151175. No abstract available.

PMID:
27134279
20.

Dr. Roubille, et al reply.

Roubille C, Richer V, Starnino T, McCourt C, McFARLANE A, Fleming P, Siu S, Kraft J, Lynde C, Pope JE, Gulliver W, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B.

J Rheumatol. 2016 May;43(5):993-4. doi: 10.3899/jrheum.151347. No abstract available.

PMID:
27134278
21.

Reduction in Serum Uric Acid May Be Related to Methotrexate Efficacy in Early Rheumatoid Arthritis: Data from the Canadian Early Arthritis Cohort (CATCH).

Lee JJ, Bykerk VP, Dresser GK, Boire G, Haraoui B, Hitchon C, Thorne C, Tin D, Jamal S, Keystone EC, Pope JE.

Clin Med Insights Arthritis Musculoskelet Disord. 2016 Apr 4;9:37-43. doi: 10.4137/CMAMD.S38092. eCollection 2016.

22.

Psoriasis and Smoking: A Systematic Literature Review and Meta-Analysis With Qualitative Analysis of Effect of Smoking on Psoriasis Severity.

Richer V, Roubille C, Fleming P, Starnino T, McCourt C, McFarlane A, Siu S, Kraft J, Lynde C, Pope JE, Keeling S, Dutz J, Bessette L, Gulliver WP, Haraoui B, Bissonnette R.

J Cutan Med Surg. 2016 May;20(3):221-7. doi: 10.1177/1203475415616073. Epub 2015 Nov 9. Review.

PMID:
26553732
23.

Use of corticosteroids in patients with rheumatoid arthritis treated with infliximab: treatment implications based on a real-world Canadian population.

Haraoui B, Jovaisas A, Bensen WG, Faraawi R, Kelsall J, Dixit S, Rodrigues J, Sheriff M, Rampakakis E, Sampalis JS, Lehman AJ, Otawa S, Nantel F, Shawi M.

RMD Open. 2015 Apr 29;1(1):e000078. doi: 10.1136/rmdopen-2015-000078. eCollection 2015.

24.

Two-year radiographic and clinical outcomes from the Canadian Methotrexate and Etanercept Outcome study in patients with rheumatoid arthritis.

Keystone EC, Pope JE, Thorne JC, Poulin-Costello M, Phan-Chronis K, Vieira A, Haraoui B; CAMEO Investigators.

Rheumatology (Oxford). 2016 Feb;55(2):327-34. doi: 10.1093/rheumatology/kev338. Epub 2015 Sep 11.

25.

Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients.

Smolen JS, van Vollenhoven R, Kavanaugh A, Strand V, Vencovsky J, Schiff M, Landewé R, Haraoui B, Arendt C, Mountian I, Carter D, van der Heijde D.

Arthritis Res Ther. 2015 Sep 10;17:245. doi: 10.1186/s13075-015-0767-2.

26.

Missing Anticitrullinated Protein Antibody Does Not Affect Short-term Outcomes in Early Inflammatory Arthritis: From the Canadian Early Arthritis Cohort.

Shu J, Bykerk VP, Boire G, Haraoui B, Hitchon C, Thorne JC, Tin D, Keystone EC, Pope JE; CATCH Investigators.

J Rheumatol. 2015 Nov;42(11):2023-8. doi: 10.3899/jrheum.150260. Epub 2015 Sep 1.

PMID:
26329342
27.

Heterogeneous Disease Trajectories Explain Variable Radiographic, Function and Quality of Life Outcomes in the Canadian Early Arthritis Cohort (CATCH).

Barnabe C, Sun Y, Boire G, Hitchon CA, Haraoui B, Thorne JC, Tin D, van der Heijde D, Curtis JR, Jamal S, Pope JE, Keystone EC, Bartlett S, Bykerk VP; CATCH Investigators.

PLoS One. 2015 Aug 24;10(8):e0135327. doi: 10.1371/journal.pone.0135327. eCollection 2015.

28.

Evidence-based Recommendations for the Management of Comorbidities in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis: Expert Opinion of the Canadian Dermatology-Rheumatology Comorbidity Initiative.

Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J, Gulliver W, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B.

J Rheumatol. 2015 Oct;42(10):1767-80. doi: 10.3899/jrheum.141112. Epub 2015 Jul 15. Review.

29.

Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update.

Stoffer MA, Schoels MM, Smolen JS, Aletaha D, Breedveld FC, Burmester G, Bykerk V, Dougados M, Emery P, Haraoui B, Gomez-Reino J, Kvien TK, Nash P, Navarro-Compán V, Scholte-Voshaar M, van Vollenhoven R, van der Heijde D, Stamm TA.

Ann Rheum Dis. 2016 Jan;75(1):16-22. doi: 10.1136/annrheumdis-2015-207526. Epub 2015 May 19. Review. Erratum in: Ann Rheum Dis. 2016 May;75(5):946.

30.

Determining the Minimally Important Difference in the Clinical Disease Activity Index for Improvement and Worsening in Early Rheumatoid Arthritis Patients.

Curtis JR, Yang S, Chen L, Pope JE, Keystone EC, Haraoui B, Boire G, Thorne JC, Tin D, Hitchon CA, Bingham CO 3rd, Bykerk VP.

Arthritis Care Res (Hoboken). 2015 Oct;67(10):1345-53. doi: 10.1002/acr.22606.

31.

The comparative effectiveness of oral versus subcutaneous methotrexate for the treatment of early rheumatoid arthritis.

Hazlewood GS, Thorne JC, Pope JE, Lin D, Tin D, Boire G, Haraoui B, Hitchon CA, Keystone EC, Jamal S, Bykerk VP; CATCH Investigators.

Ann Rheum Dis. 2016 Jun;75(6):1003-8. doi: 10.1136/annrheumdis-2014-206504. Epub 2015 May 15.

PMID:
25979945
32.

Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force.

Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, Kvien TK, Navarro-Compán MV, Oliver S, Schoels M, Scholte-Voshaar M, Stamm T, Stoffer M, Takeuchi T, Aletaha D, Andreu JL, Aringer M, Bergman M, Betteridge N, Bijlsma H, Burkhardt H, Cardiel M, Combe B, Durez P, Fonseca JE, Gibofsky A, Gomez-Reino JJ, Graninger W, Hannonen P, Haraoui B, Kouloumas M, Landewe R, Martin-Mola E, Nash P, Ostergaard M, Östör A, Richards P, Sokka-Isler T, Thorne C, Tzioufas AG, van Vollenhoven R, de Wit M, van der Heijde D.

Ann Rheum Dis. 2016 Jan;75(1):3-15. doi: 10.1136/annrheumdis-2015-207524. Epub 2015 May 12. Review.

33.

Response to: 'drugs and cardiovascular risk in inflammatory arthritis: another case of glucocorticoid-bashing?' by Dr Boers.

Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J, Gulliver W, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B.

Ann Rheum Dis. 2015 May;74(5):e34. doi: 10.1136/annrheumdis-2015-207419. Epub 2015 Mar 9. No abstract available.

PMID:
25755140
34.

Attitudes towards subsequent entry biologics/biosimilars: A survey of Canadian rheumatologists.

Grabowski D, Henderson B, Lam D, Keystone EC, Thorne C, Jamal S, Pope J, Haraoui B, Lin D, Revers L.

Clin Rheumatol. 2015 Aug;34(8):1427-33. doi: 10.1007/s10067-014-2835-4. Epub 2015 Jan 15.

PMID:
25586522
35.

The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis.

Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J, Gulliver W, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B.

Ann Rheum Dis. 2015 Mar;74(3):480-9. doi: 10.1136/annrheumdis-2014-206624. Epub 2015 Jan 5. Review.

36.

Arthritis clinical trials at a crossroad.

Pope JE, Thorne JC, Haraoui BP, Karsh J, Keystone EC, Bennett L.

J Rheumatol. 2015 Jan;42(1):14-7. doi: 10.3899/jrheum.140717. No abstract available.

PMID:
25554805
37.

Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis.

Westhovens R, Robles M, Ximenes AC, Wollenhaupt J, Durez P, Gomez-Reino J, Grassi W, Haraoui B, Shergy W, Park SH, Genant H, Peterfy C, Becker JC, Murthy B.

Ann Rheum Dis. 2015 Mar;74(3):564-8. doi: 10.1136/annrheumdis-2014-206149. Epub 2014 Dec 30.

38.

Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review.

Fleming P, Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Siu S, Kraft J, Lynde C, Pope JE, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B, Gulliver WP.

J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1063-70. doi: 10.1111/jdv.12909. Epub 2014 Dec 10. Review.

PMID:
25490866
39.

Meta-analysis of tumor necrosis factor inhibitors and glucocorticoids on bone density in rheumatoid arthritis and ankylosing spondylitis trials.

Siu S, Haraoui B, Bissonnette R, Bessette L, Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Kraft J, Lynde C, Gulliver W, Keeling S, Dutz J, Pope JE.

Arthritis Care Res (Hoboken). 2015 May;67(6):754-64. doi: 10.1002/acr.22519. Review.

40.

Does socioeconomic status affect outcomes in early inflammatory arthritis? Data from a canadian multisite suspected rheumatoid arthritis inception cohort.

Yang G, Bykerk VP, Boire G, Hitchon CA, Thorne JC, Tin D, Haraoui B, Keystone EC, Pope JE; CATCH Investigators.

J Rheumatol. 2015 Jan;42(1):46-54. doi: 10.3899/jrheum.131382. Epub 2014 Nov 15.

PMID:
25399388
41.

Is structural damage evaluation by traditional radiographs still relevant in rheumatoid arthritis clinical trials?

Haraoui B, Karsh J, Pope JE, Thorne JC, Keystone EC.

J Rheumatol. 2014 Nov;41(11):2325. doi: 10.3899/jrheum.140383. No abstract available.

PMID:
25362720
42.

Effect of age at menopause on disease presentation in early rheumatoid arthritis: results from the Canadian Early Arthritis Cohort.

Wong LE, Huang WT, Pope JE, Haraoui B, Boire G, Thorne JC, Hitchon CA, Tin D, Keystone EC, Bykerk VP; Canadian Early Arthritis Cohort Investigators.

Arthritis Care Res (Hoboken). 2015 May;67(5):616-23. doi: 10.1002/acr.22494.

43.

Earlier time to remission predicts sustained clinical remission in early rheumatoid arthritis--results from the Canadian Early Arthritis Cohort (CATCH).

Kuriya B, Xiong J, Boire G, Haraoui B, Hitchon C, Pope J, Thorne JC, Tin D, Keystone EC, Bykerk V; CATCH Investigators.

J Rheumatol. 2014 Nov;41(11):2161-6. doi: 10.3899/jrheum.140137. Epub 2014 Oct 1.

PMID:
25274902
44.

Prognosis of seronegative patients in a large prospective cohort of patients with early inflammatory arthritis.

Barra L, Pope JE, Orav JE, Boire G, Haraoui B, Hitchon C, Keystone EC, Thorne JC, Tin D, Bykerk VP; CATCH Investigators.

J Rheumatol. 2014 Dec;41(12):2361-9. doi: 10.3899/jrheum.140082. Epub 2014 Oct 1.

PMID:
25274884
45.

Treating rheumatoid arthritis to target: a Canadian patient survey.

Haraoui B, Bensen W, Thorne C, Wade J, Deamude M, Prince J, Légaré J.

J Clin Rheumatol. 2014 Mar;20(2):61-7. doi: 10.1097/RHU.0000000000000081.

PMID:
24561407
46.

Are there differences between young- and older-onset early inflammatory arthritis and do these impact outcomes? An analysis from the CATCH cohort.

Arnold MB, Bykerk VP, Boire G, Haraoui BP, Hitchon C, Thorne C, Keystone EC, Pope JE; CATCH Investigators.

Rheumatology (Oxford). 2014 Jun;53(6):1075-86. Review.

PMID:
24501240
47.

Clinical, functional, and radiographic implications of time to treatment response in patients with early rheumatoid arthritis: a posthoc analysis of the PREMIER study.

Keystone EC, Haraoui B, Guérette B, Mozaffarian N, Liu S, Kavanaugh A.

J Rheumatol. 2014 Feb;41(2):235-43. doi: 10.3899/jrheum.121468. Epub 2013 Dec 1.

48.

Physician global assessment at 3 months is strongly predictive of remission at 12 months in early rheumatoid arthritis: results from the CATCH cohort.

Choy T, Bykerk VP, Boire G, Haraoui BP, Hitchon C, Thorne C, Keystone EC, Pope JE; CATCH Investigators.

Rheumatology (Oxford). 2014 Mar;53(3):482-90. doi: 10.1093/rheumatology/ket366. Epub 2013 Nov 15.

PMID:
24241035
49.

Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review.

Roubille C, Haraoui B.

Semin Arthritis Rheum. 2014 Apr;43(5):613-26. doi: 10.1016/j.semarthrit.2013.09.005. Epub 2013 Oct 5. Review.

PMID:
24231065
50.

Preparing for subsequent entry biologics in dermatology and rheumatology in Canada.

Papp K, Bourcier M, Ho V, Burke K, Haraoui B.

J Cutan Med Surg. 2013 Sep-Oct;17(5):340-6.

PMID:
24067855

Supplemental Content

Loading ...
Support Center